Press releases

* (R) = Regulatory press releases

Nov 9, 2017

(R) Cantargia: Combined directed issue and fully guaranteed rights issue of 232 MSEK for its expanded clinical program of immuno-oncology antibody CAN04
Nov 8, 2017

(R) Cantargia publishes interim report for third quarter of 2017
Nov 1, 2017

(R) Cantargia announces a new date for the third quarter interim report
Oct 13, 2017

(R) Cantargia announces first patient treated and completed a three weeks safety evaluation period with immuno-oncology antibody CAN04
Oct 6, 2017

(R) Cantargia obtains patent approval in USA for the antibody CAN04 in development for treatment of cancer
Aug 31, 2017

(R) Cantargia obtains patent approval in Europe for the antibody CAN04 in development for treatment of cancer
Aug 23, 2017

(R) Cantargia publishes half year report
Jul 21, 2017

(R) Cantargia gains approval to initiate the CANFOUR clinical trial of immuno-oncology product candidate CAN04
Jun 26, 2017

(R) Cantargia: Preclinical studies of IL1RAP and CAN04 in solid tumours presented at EACR-AACR-SIC in Florence
Jun 21, 2017

(R) Cantargia receives Notice of Allowance in the US for the CAN04 patent application
<< Newer press releases    Older press releases >>

In media

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2024-12-10

Redeye

Interview with CEO VD Göran Forsberg (In Swedish) - 2024-12-10

BioStock

Redeye interviews CEO Göran Forsberg about the expansion of CAN10's phase 1 study (In Swedish) - 2024-12-02

Redeye

Interview with CEO Göran Forsberg about the expansion of CAN10's phase 1 study and rights issue (In Swedish) - 2024-12-02

Biostock

Interview with CEO Göran Forsberg about the latest results from the phase 1 study of CAN10 and the development of nadunolimab in pancreatic cancer - 2024-10-14

Redeye

Interview with CEO Göran Forsberg about new results from the phase 1 study of CAN10 - 2024-08-12

Redeye

Interview with CEO Göran Forsberg regarding new results in pancreatic cancer - 2024-06-28

Redeye

Interview with CEO Göran Forsberg about the new neuropathy results with nadunolimab in pancreatic cancer that will be presented at ASCO. (In Swedish) - 2024-05-24

Redeye

CEO Göran Forsberg interviewed on new results with CAN10 and external validation of IL-1 blockade during inflammatory disease. (In Swedish) - 2023-03-15

Redeye

Redeye interviews CEO Göran Forsberg about new results on nadunolimab and alleviation of neuropathy during chemotherapy. (In Swedish) - 2024-02-14

Redeye

COO Liselotte Larsson presents at Redeye Life Science Day - 2023-11-23

Redeye

CEO Göran Forsberg comments on the quarterly report (In Swedish) - 2023-11-10

Di TV

Interview with CEO Göran Forsberg about the directed share issue (In Swedish) - 2023-10-31

Redeye

Interview with CEO Göran Forsberg about new TRIFOUR results (In Swedish) - 2023-10-23

Redeye

CEO Interview, New results for nadunolimab monotherapy and IL1RAP as a biomarker presented at AARC (In Swedish) - 2023-10-02

Redeye

CEO Interview, about expanded clinical pipeline and start of treatment in CAN10, for autoimmune diseases. (In Swedish) - 2023-09-05

Redeye

CEO interview, about the new readout from trials in non-small cell lung cancer - 2023-05-31

Redeye

CEO interview, Interim efficacy results nadunolimab (In Swedish) - 2023-05-31

Västra Hamnen Corporate Finance

CEO interview, Promising interim efficacy results for nadunolimab in lung cancer - 2023-05-26

Di TV

Cantargia presents updated interim results - 2023-05-26

Di TV

CEO interview, New clinical development strategy for nadunolimab in pancreatic cancer - 2023-05-17

Redeye

CEO interview, Positive results published at the AARC-conference 2023 - 2023-04-19

Redeye

CEO interview, New positive research results (In Swedish) - 2023-03-15

DiTV

CEO interview, CANFOUR new Biomarker data (In Swedish)- 2023-03-15

Redeye

CEO interview, TRIFOUR result (In Swedish)- 2023-02-23

Redeye

CEO interview, Redeye Life Science Day (In Swedish) - 2022-11-24

Redeye

CEO interview, Edison - 2022-06-24

Edison

CEO interview, Rights issue, Redeye (In Swedish) - 2022-06-22

Redeye

CEO interview, Edison - 2022-03-16

Edison

Panel discussion – Business development

Redeye

CEO interview, Redeye, (In Swedish) - 2021-08-31

Redeye

CEO interview, Di TV (In Swedish) - 2021-05-26

Di TV

CEO presentation AGM (In Swedish) - 2021-05-26

Bio Stock

CEO interview, Redeye, (In Swedish) - 2021-05-24

Redeye

CEO interview, Redeye, (In Swedish) - 2021-05-11

Redeye

Interview with CEO Göran Forsberg and CMO Ignacio Garcia-Ribas, Pareto - 2021-03-26

Pareto Securities

CEO interview, Edison - 2021-03-15

Edison

CEO interview, Redeye, (In Swedish) - 2021-03-09

Redeye

Cantargia in a panel discussion on how to build a successful biotech company (In Swedish) - 2021-01-27

Aktiespararna

CEO interview, Edison Open House - 2021-01-26

Edison

CEO interview, direct share issue, Redeye (In Swedish) - 2020-12-16

Redeye

CEO interview, direct share issue, Di TV (In Swedish) - 2020-12-16

Di TV

CEO interview, EFN (In Swedish) - 2020-10-16

EFN

CEO interview, Penser Bank Cancer Research Day (In Swedish) - 2020-10-07

Penser Bank

Article about Cantargias antibody based cancer treatment with multiple functions 2019-10-31

Affärstidningen Näringsliv

Presentation at ASCO 2019, follow up articles and interviews - 2019-07-02

ASCO

Cantargia interview at EFN after ASCO - 2019-06-17

EFN

CEO interview, Edison, London - 2019-02-26

Edison TV

CEO interview, EFN, Lund (In Swedish) - 2018-11-22

EFN

Interview around CAN04 clinical results, Redeye, Stockholm (In Swedish) - 2018-10-23

Redeye

Listing ceremony for Cantargia on Nasdaq Stockholm Main Market - 2018-09-25

Nasdaq

CEO interview in connection with listing Nasdaq Stockholm (Small Cap), EFN, Stockholm (In Swedish) - 2018-09-25

EFN

CEO interview in connection with listing Nasdaq Stockholm (Small Cap), Ditv, Stockholm (In Swedish) - 2018-09-25

Di

CEO interview, Redeye, Stockholm (In Swedish) 2018-09-06

Redeye

CEO interview, BioStock Live, Stockholm (In Swedish) -2018-08-29

Direkt Studios

Småbolagspanelen: Om framtidens cancerbehandlingar, Småbolagsdagen, Stockholm (in Swedish) 2018-06-11

Aktiespararna

CEO interview BioStock Live, Stockholm (In Swedish) -2018-03-20

Direkt Studios

CEO-interview 2017-12-12

Aktiespararna

Interview with Cantargia's CEO Göran Forsberg after the presentation at BioStock Live i Stockholm - 2017-12-04

Direkt Studios

CEO interview - 2017-11-29

Finwire.tv

Video, interview Göran Forsberg, President Cantargia, Sedermera-dagen, Lund - 2016-03-16

Finwire.tv

CONTACT US
Cantargia AB
Scheelevägen 27
SE-223 63 Lund, Sweden

E-mail: info@cantargia.com
Switch board: +46(0)46 2756260

Privacy Policy

Subscribe to our press releases

© Copyright 2025 · Cantargia AB